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HIF drives lipid deposition and cancer in ccRCC via
repression of fatty acid metabolism
Weinan Du1, Luchang Zhang1, Adina Brett-Morris1, Brittany Aguila1, Janos Kerner2, Charles L. Hoppel2,3,
Michelle Puchowicz4, Dolors Serra5,6, Laura Herrero 5,6, Brian I. Rini7, Steven Campbell8 & Scott M. Welford1
Clear cell renal cell carcinoma (ccRCC) is histologically deﬁned by its lipid and glycogen-rich
cytoplasmic deposits. Alterations in the VHL tumor suppressor stabilizing the hypoxia-
inducible factors (HIFs) are the most prevalent molecular features of clear cell tumors. The
signiﬁcance of lipid deposition remains undeﬁned. We describe the mechanism of lipid
deposition in ccRCC by identifying the rate-limiting component of mitochondrial fatty acid
transport, carnitine palmitoyltransferase 1A (CPT1A), as a direct HIF target gene. CPT1A is
repressed by HIF1 and HIF2, reducing fatty acid transport into the mitochondria, and forcing
fatty acids to lipid droplets for storage. Droplet formation occurs independent of lipid source,
but only when CPT1A is repressed. Functionally, repression of CPT1A is critical for tumor
formation, as elevated CPT1A expression limits tumor growth. In human tumors, CPT1A
expression and activity are decreased versus normal kidney; and poor patient outcome
associates with lower expression of CPT1A in tumors in TCGA. Together, our studies identify
HIF control of fatty acid metabolism as essential for ccRCC tumorigenesis.
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C lear cell renal cell carcinoma (ccRCC) is the most commonform of renal cancer, and the most deleterious tumorafﬂicting cancer-prone von Hippel–Lindau patients. Clear
cell tumors are deﬁned histologically as malignant epithelial cells
with clear cytoplasm, owing to a vast accumulation of lipids and
glycogen that are removed in standard histological preparations1.
While great strides have been made in identifying the genetic
alterations driving ccRCC development2, the signiﬁcance of, and
molecular mechanisms leading to, the clear cell phenotype are
incompletely appreciated.
The canonical molecular alteration in ccRCC is inactivation of
the von Hippel–Lindau tumor suppressor (VHL) located on
chromosome 3p. Whether due to genetic predisposition, as in the
case of von Hippel–Lindau disease, or due to somatic mutations
or methylation, VHL alterations have been estimated to occur in
near 90% of all clear cell tumors3, 4. A principal role of VHL is in
the regulation of hypoxia-inducible factors involved in oxygen
sensing. As an E3 ubiquitin ligase, VHL inactivation leads to
constitutive activation of HIF1 and HIF2 through the stabilization
of oxygen labile HIFα subunits5. Subsequent activation of hypoxic
gene expression downstream of HIF1 and HIF2 is thought to be a
major driving force in ccRCC development, and has led to tar-
geted therapeutic strategies aimed at the well-described HIF target
gene vascular endothelial growth factor (e.g., Sunitinib) that have
become the standard of care6.
Gene expression programs activated by HIFs in cancer include
angiogenesis, anaerobic metabolism, inﬂammation, and metas-
tasis7. A recent analysis of programs altered in ccRCC compared
to normal kidneys identiﬁed an adipogenic gene signature, and
led to studies that demonstrated that ccRCC cells can undergo
trans-differentiation when exposed to established adipogenic
differentiation protocols8, suggesting some mechanistic insight
into the lipid deposition phenotype. Notably, adipogenic differ-
entiation in vitro is associated with terminal cessation of the cell
cycle, unlike the behavior of tumor cells. Nonetheless, ccRCC
clearly display a propensity for lipid deposition rather than lipid
catabolism.
Fatty acid (FA) synthesis is an anabolic process that responds
to excess citrate in the cytoplasm9. Metabolism of glucose under
aerobic conditions produces pyruvate, which enters the citric acid
cycle in mitochondria by the action of pyruvate dehydrogenase to
produce acetyl-CoA, and then citrate-by-citrate synthase. Citrate
can also be produced from metabolism of glutamine via α-
ketoglutarate in cancer cells, either through forward ﬂux through
oxaloacetate, or through reverse cycle activity of isocitrate dehy-
drogenase and aconitase10, as recently observed in ccRCC11.
Excess mitochondrial citrate is exported to the cytosol, where it is
a substrate for ATP citrate lyase to produce cytosolic acetyl-CoA.
Subsequently carboxylation of acetyl-CoA by acetyl-CoA car-
boxylase to form malonyl-CoA is the commitment step in FA
synthesis. The principal roles of FAs are to serve as substrates for
membrane synthesis, energy stores, and production of signaling
molecules. Abnormal cancer metabolism leads to changes in
decisions regarding FA fates, including the altered balance in
ccRCC toward excessive storage in the form of lipids. FA meta-
bolism via ER-bound enzymes leads to production of diacylgly-
cerol, which can then be stored as triglycerides in the lipid
droplet; while FA transport into the mitochondrion via CPT1
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Fig. 1 Lipid accumulation in ccRCC cells is VHL dependent. a Photomicrographs of RCC4, RCC10, and 786-O renal cell lines with or without VHL stained
with Oil Red O 6 days after reaching conﬂuence. b Western blot demonstrating VHL expression in reconstituted lines. β-actin used as loading control. c
Quantiﬁcation of Oil Red O extracted from cells shown in a. d Oil Red O staining of RCC4 cells 2 days after treatment with linoleic/oleic acid (LA/OA). e
Quantiﬁcation of Oil Red O staining of cells in d. f Quantiﬁcation of Oil Red O staining of RCC4 VHL cells treated with LA/OA cultured in either normoxia
(N) or 1% oxygen (H). Statistical tests for all panels were two-tailed Student’s t tests. Scale bar= 10 μm. Error bars represent standard deviations
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leads to beta oxidation and the regeneration of acetyl-CoA for
entry into the critic acid cycle and the generation of reducing
equivalents for ATP.
The goal of the current study was to determine the molecular
mechanisms driving lipid deposition in ccRCC. To this point, it
has remained unclear whether accumulation of lipids is a
byproduct of altered metabolism in ccRCC, or whether lipid
storage contributes to disease development. Here we deﬁne the
rate-limiting enzyme of the FA transport system controlling entry
into the mitochondrion, carnitine palmitoyltransferase 1A
(CPT1A), as a hypoxia-repressed target gene that regulates lipid
accumulation in ccRCC. CPT1A is shown to be a direct target
gene of the HIF1 and HIF2 complexes and repressed in a VHL-
dependent manner in ccRCC cells leading to reduced FA cata-
bolism. Reintroduction of CPT1A into VHL-defective cells not
only reverses the lipid deposition phenotype, but importantly
reduces tumor growth in vivo. Analyses of clinical samples con-
ﬁrm the decreased expression and activity of CPT1A in renal
tumors compared to normal kidney samples. Together, the
ﬁndings highlight the importance of altered lipid metabolism in
contributing to ccRCC, and suggest that targeting lipid metabo-
lism in may be a new avenue for therapeutic intervention in renal
cancer.
Results
Lipid deposition in ccRCC is VHL mediated. To begin to dissect
the mechanism of lipid deposition in ccRCC cells, we evaluated
the ability of three ccRCC cell lines (RCC4, RCC10, and 786-O)
to make lipid droplets. While others have found that ccRCC
tumors demonstrate an adipogenic gene expression signature,
and an ability to differentiate in vitro under an adipogenic dif-
ferentiation protocol8, we reasoned that terminal differentiation
that is not characteristic of renal tumors might not be the only
way to induce lipid deposits in ccRCC cells. Instead, we evaluated
the formation of lipid droplets in conﬂuent monolayers. We
found that all three cell lines developed lipid droplets as revealed
by Oil Red O staining (Fig. 1a, upper panels) at 2–8 days after
reaching conﬂuence. In contrast, VHL reconstituted RCC4,
RCC10, and 786-O cells (Fig. 1b) displayed a dramatic reduction
in lipid droplet formation under the same conditions (Fig. 1a,
lower panels). Quantiﬁcation of the lipids after Oil Red O
extraction normalized to cell number demonstrated that RCC4
cells accumulated greater than ﬁve times the lipid deposits
compared to RCC4 VHL cells (Fig. 1c); RCC10 cells had greater
than 2.25 times the lipids than RCC10 VHL cells; and 786-O cells
accumulated 3.7-fold more lipids than 786-O VHL cells. Thus,
ccRCC cells can indeed accumulate lipid droplets in vitro, as
ccRCC tumors are characterized to do in vivo, without under-
going adipogenic differentiation. Moreover, lipid deposition in
ccRCC cells depends on loss of the VHL tumor suppressor.
We next tested whether lipogenesis could be induced by
treatment of ccRCC cells with cis-unsaturated fatty acids like
linoleic (18:2) and oleic (18:1) acid (LA/OA) in subconﬂuent cells.
LA/OA treatement has long been known to induce lipid droplets
in adipocytes, but not kidney epithelial cells12. Indeed, we
observed that RCC4 cells treated with 200 μM LA/OA, which is
equivalent to the levels circulating in people consuming the
western diet13, more rapidly formed lipid droplets than untreated
cells (Fig. 1d). Quantiﬁcation of lipid droplet accumulation
revealed greater than seven times the accumulation after 2 days of
treatment in the LA/OA-treated RCC4 cells compared to the
untreated cells (Fig. 1e). Finally, we tested whether the formation
of droplets could be induced in RCC4 VHL cells when the cells
were cultured under hypoxic conditions, and found hypoxia
could potently induce lipid deposition in the presence or absence
of LA/OA (Fig. 1f), suggesting a model that by regulating the
hypoxia pathway, VHL negatively regulates lipid accumulation in
renal cancer cells.
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Fig. 2 Lipid accumulation is dependent on glucose, but independent of glutamine. a Photomicrographs of Oil Red O-stained 786-O cells cultured in the
presence or absence of serum and glutamine, as indicated. Bar= 10 μm. b Crystal violet staining of rescued cells from treatment as in a. Bar= 1 cm. c
Photomicrographs of Oil Red O-stained 786-O cells cultured in indicated glucose concentrations. d Quantiﬁcation of Oil Red O of cells in c and graphed
versus glucose concentration. Square of the Pearson correlation coefﬁcient r is shown. e Quantiﬁcation of Oil Red O of 786-O cells with media changes 0,
2, or 3 times during the 7-day period. f Fluorescent labeling of BrdU incorporation of 786-O cells at subconﬂuent or at 7 days post conﬂuence. Bar= 10 μm.
p values of two-tailed Student’s t tests are displayed. Error bars represent standard deviations
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Lipid droplet formation requires glucose, but not glutamine.
Recent studies have described vast rewiring of metabolic path-
ways in renal cell carcinomas to promote the Warburg effect,
involving the metabolism of glutamine in reverse carboxylation to
produce lipids and energy in place of the citric acid cycle in the
mitochondria10, 11. We thus wondered if lipid deposition was
dependent on glutamine metabolism, and tested droplet forma-
tion in 786-O cells in the presence or absence of glutamine. Cells
were plated at conﬂuence and observed for 7 days, and found to
robustly form droplets in a glutamine-independent manner
(Fig. 2a). Recent reports have demonstrated the dependence of
ccRCC cells on glutamine as a primary carbon source for survival.
Notably, very few cells were still attached to the surface of the
plates, but the cells that survived demonstrated signiﬁcant lipid
droplet formation. To rule out the possibility that glutamine was
present in the charcoal-stripped serum with which the medium
was supplemented, we also performed the assay in the absence of
both serum and glutamine and found similar results, and also
noted that the remaining cells remained viable and maintained
clonogenic capacity depending on how long they were starved
(Fig. 2b). In contrast, droplet formation was highly dependent on
the presence of glucose (Fig. 2c, d). Glucose concentration pro-
duced a dose-dependent increase in Oil Red O staining, occurring
in the physiologic glucose range (1 g/L) as well as the standard
culture range (4.5 g/L), and demonstrated an almost perfect
correlation between glucose concentration and lipid droplet for-
mation (correlation coefﬁcient R2 of 0.968). Droplet formation
was found to be unrelated to nutrient exhaustion because chan-
ging the media during the course of deposition at either 2- or 3-
day intervals did not diminish the production (Fig. 2e), and
interestingly proliferation state revealed by BrdU labeling did not
change up to 7 days post conﬂuence, suggesting that droplet
formation is not a postmitotic phenomenon (Fig. 2f). Together,
the observations suggest lipid droplet formation in ccRCC cells is
highly dependent on glucose rather than glutamine and is not a
result of adverse culture conditions.
Lipid uptake is not altered by VHL status. We next assessed
whether the differences between VHL competent and deﬁcient
cells in lipid deposition were due to differences in fatty acid
uptake. A variety of fatty acid transporters, including CD36 and
LRP1, have ties to hypoxia in other model systems, and could be
involved in a VHL-dependent response in RCC14–16. To deter-
mine if lipid uptake is altered in VHL-deﬁcient RCC cells, we
used a ﬂuorescent cis-unsaturated fatty acid molecule (BODIPY
500/510 C1, C12 (4,4-diﬂuoro-5-methyl-4-bora-3a,4a-diaza-S-
indacene-3-dodecanoic acid)), and monitored fatty acid uptake
visually over time. As can be seen in Fig. 3a, b, VHL status had no
effect on lipid uptake rates in RCC4 or RCC10 cells over a 90-min
period as measured by ﬂuorescent quantiﬁcation. In contrast,
ﬂuorescent images at 24 h demonstrated signiﬁcant differences in
lipid localization between the VHL-expressing cells and the par-
ental VHL-deﬁcient cells (Fig. 3c). In agreement with the Oil Red
O staining, BODIPY was localized in foci reminiscent of lipid
droplets in the RCC4 cells, but was diffuse in the RCC4 VHL
cells. To speciﬁcally rule out CD36, an hypoxia-inducible sca-
venger receptor for oxidized low-density lipoprotein and long-
chain fatty acids14, as a mediator of lipid uptake, we performed
shRNA knockdown of CD36 in RCC4 cells (Fig. 3d) and found
that almost complete knockdown had non-signiﬁcant effects on
lipid droplet formation (Fig. 3e). Thus, lipid uptake appears to be
unable to explain the differences in droplet formation; rather,
lipid catabolism appears altered.
Lipid droplet formation is dependent on HIF. As HIF is the
major mediator of VHL-dependent functions, we investigated the
roles of HIF1α and HIF2α in lipid accumulation in ccRCC cells.
Both HIF isoforms were inactivated by shRNA in RCC4 cells
either alone or in combination, as demonstrated by western blot
in Fig. 4a, and the cells were tested for lipid accumulation post
conﬂuency. Knockdown of either HIF isoform resulted in a sta-
tistically signiﬁcant decrease in droplet formation compared to
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Fig. 3 Lipid deposition in VHL-deﬁcient cells is not due to altered fatty acid import. a Quantiﬁcation of ﬂuorescence in RCC4 and RCC4 VHL cells at
indicated times after exposure to BODIPY-dodecanoic acid. b Quantiﬁcation of ﬂuorescence in RCC10 and RCC10 VHL cells at indicated times after
exposure to BODIPY-dodecanoic acid. c Representative ﬂuorescent images of BODIPY-labeled RCC4 and RCC4 VHL cells at 24 h after exposure to
BODIPY-dodecanoic acid. Bar= 10 μm. d Quantitative real-time PCR detection of CD36 expression after shRNA knockdown. e Quantiﬁcation of Oil Red O
staining of RCC4 cells with shGFP or shCD36 knockdown. Error bars represent standard deviations. p values of two-tailed Student’s t tests are displayed
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the shGFP control cells, ranging from 23% for the HIF1α
knockdown to 42% for the HIF2α knockdown (Fig. 4b, c; p =
0.004 and 0.0004, respectively, Student’s t tests). The most dra-
matic decrease resulted from the double knockdown of HIF1α
and HIF2α (p< 0.0001, Student’s t test), demonstrating the HIF
dependence of lipid storage in RCC cells.
Lipid synthesis begins ostensibly as excess citrate accumulates in
the cytosol is converted to acetyl-CoA and becomes a substrate for
acetyl-CoA carboxylase and subsequently fatty acid synthase9.
Fatty acids are then activated by acyl-CoA synthase, and are either
shuttled back into the mitochondria after modiﬁcation by carnitine
palmitoyltransferase 1 (CPT1A) on the mitochondrial outer
membrane, or are further modiﬁed into di- and triglycerides for
storage in the lipid droplet. CPT1A is the rate-limiting step in
determining FA oxidation or storage. Because we observed lipid
droplet formation in ccRCC cells in a glucose or FA-dependent
manner, we investigated steps downstream from FA anabolism.
We ﬁrst measured the levels of CPT1A in RCC4 cells depleted for
HIF1α, HIF2α, or both, and found expression of CPT1A to be
inversely related to the levels of either HIF1α or HIF2α (Fig. 4a), in
agreement with a model of increased HIF in response to VHL
inactivation leading to decreased CPT1A and subsequently
increased lipid storage. We measured the activity of CPT1A in
RCC4 and RCC4 VHL mitochondria and found a correlated
increase in relative activity in the presence of VHL (Fig. 4d). To
determine directly the effect of CPT1A depletion on droplet
formation, we used shRNA to reduce CPT1A message (Fig. 4e),
and then monitored lipid droplet formation in RCC4 VHL cells. As
shown in Fig. 4f, all three knockdown constructs dramatically
increased lipid deposition compared to the control RCC4 VHL
shGFP cells, in the range of three-fourfold (Fig. 4g). Lastly, we
asked whether conﬂuence inﬂuences CPT1A expression since we
noted that lipid accumulation occurs more robustly at post-
conﬂuent conditions and observed a modest but reproducible
decrease in both the RCC4 and 786-O cells that appeared to be HIF
independent because no correlating changes were seen in GLUT1
(Fig. 4h). Thus, CPT1A repression by the HIF pathway mediates
the effects of VHL loss regarding lipid storage.
HIF1 and HIF2 bind the CPT1A locus and inhibit expression.
To delineate how HIF regulates CPT1A, we assessed the effect of
hypoxia on CPT1A message and protein levels in RCC4 and
RCC4 VHL cells. Introduction of VHL into RCC4 cells led to a
>fourfold increase in CPT1A mRNA (Fig. 5a), while treatment of
RCC4 VHL cells with 1% oxygen for 24 h reversed the effect
almost completely. At the protein level, similar results were
observed. Introduction of VHL led to a drop in HIF1α levels, and
an inversely coordinated increase in CPT1A; both of which were
reversed by hypoxia exposure (Fig. 5b). Because HIF is not
typically considered a direct transcriptional repressor17, we next
assessed the contribution of two transcriptional repressors that
are induced by HIF stabilization, Snail and DEC1, that from the
literature might be predicted to be involved in metabolic changes.
DEC1 has recently been identiﬁed as the mechanism through
which HIF suppresses PGC1α and reduces mitochondrial
respiration18; while Snail affects glucose metabolism19. Unex-
pectedly, however, knockdown of neither Snail (Fig. 5c) nor
DEC1 (Fig. 5d) in RCC4 cells was able to alleviate the suppression
of CPT1A, in spite of elevated expression of E-cadherin (Snail
target20) or PGC1α (DEC1 target18), respectively. Conversely,
knockdown of CPT1A did lead to a reduction in PGC1α
expression suggesting some overlap of the pathways (Fig. 5e), but
the data clearly distinguish CPT1A from DEC1. PLIN2, another
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recently described HIF target involved in lipid droplet biology21
also appears unrelated to CPT1A regulation (Fig. 5e). Thus, the
mechanism of regulation of CPT1A by HIF appears distinct from
other known metabolic effectors.
We next examined the 10 kilobases surrounding the transcrip-
tional start site of CPT1A to see if potential HIF response
elements (HRE) could be found bioinformatically. MatInspector
analysis (Genomatix.com) revealed 12 putative HREs throughout
the region (Fig. 5f). We designed eight primer pairs speciﬁc for
each HRE region, grouping those that fell within 50–100 base
pairs of each other, and performed chromatin immunoprecipita-
tion (ChIP) with either HIF1α or HIF2α-speciﬁc antibodies.
RCC4 VHL cells were treated with 1% oxygen for 24 h, and then
harvested for ChIP. We found that of the eight primer pairs,
region 2 was enriched in both the HIF1α and HIF2α pull-down
experiments after hypoxia treatment, suggesting HIF1α or HIF2α
can both bind speciﬁcally to the CPT1A promoter in a hypoxia-
dependent manner (Fig. 5g). We tested whether HIF1α could
bind and regulate CPT1A under normoxic conditions in RCC4
VHL cells by treating the cells with the HIF prolyl-hydroxylase
inhibitor dimethyloxalylglycine, N-(methoxyoxoacetyl)-glycine
methyl ester (DMOG, 1 mM, 36 h); and in RCC4 cells which
have high basal HIF1α due to the lack of VHL. We found both an
increase in HIF1α association and a concurrent decrease in
CPT1A message under normoxia in both situations, suggesting
HIF activation is sufﬁcient for the effect rather than requiring
additional hypoxia-mediated changes (Fig. 5h, i). We then asked
whether hypoxic regulation of the CPT1A promoter altered
epigenetic marks near the start site that are associated with
expression versus silencing. ChIP of RCC4 VHL cells treated with
hypoxia demonstrated that an increase in GLUT1 mRNA (Fig. 5j)
was associated with a decrease in histone H3 lysine 9
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trimethylation (H3K9me3) of the GLUT1 promoter (Fig. 5k).
Accordingly, hypoxia led to a decrease in CPT1A mRNA and a
robust increase in trimethylation of lysine 9. Together, we
conclude that hypoxia leads to a silencing of CPT1A transcrip-
tionally in a HIF-dependent, non-canonical manner.
CPT1A restoration blocks lipid accumulation and tumor-
igenesis. While lipid deposition has long been a deﬁning char-
acteristic of ccRCC, the signiﬁcance of the change in lipid
metabolism to tumorigenesis remains unclear. To assess the
effects of restoring CPT1A levels in ccRCC cells, we infected
RCC4 and 786-O cells with an adenovirus encoding a con-
stitutively active form of rat CPT1A that is not inhibited by
malonyl-CoA (called CPT1AM) and assessed changes to lipid
deposition and tumor growth. Adenoviral transduction led to
dramatic increases in expression of CPT1A (Fig. 6a), and asso-
ciated decreases in the ability of both RCC4 and 786-O cells to
produce droplets (Fig. 6b). Quantiﬁcation of droplet formation
conﬁrmed this observation (Fig. 6c). We conﬁrmed the function
of CPT1A by testing activity in the infected cells and found a
greater than twofold increase (Fig. 6d), similar to the change seen
in RCC4 compared to RCC4 VHL cells (Fig. 4d). In accordance
with increased lipid oxidation, elevation of CPT1A increased
oxygen consumption (Fig. 6e) and citrate levels (Fig. 6f), in line
with changes observed in ccRCC due to VHL loss11. Acetyl-CoA
levels, however, did not change appreciably (Fig. 6g), perhaps due
to compensatory mechanisms.
We next assessed the ability of CPT1A-restored cells to form
tumors in nude animals; 786-O cells were injected subcutaneously
into the ﬂanks of nude mice, and followed over a period of 6 weeks.
CPT1A restoration led to signiﬁcant decreases in tumor growth, as
assessed by two-way ANOVA (p = 0.0034) (Fig. 7a). Notably, we
extracted protein lysates from a number of tumors, and observed
that all of the CPT1A-expressing tumors had lost expression by the
end of the assay (Fig. 7b), which is not surprising due to the
transient nature of adenoviral gene transfer. In contrast, one tumor
that was harvested at the size of 60mm3 was stained for CPT1A
expression by immunoﬂuorescence and with Oil Red O for lipid
droplet detection revealed abundant CPT1A and sparse lipid
deposition compared to a control tumor (Fig. 7c).
We next wanted to determine whether stable expression of
CPT1A could lead to more profound effects on tumor growth,
and thus turned to creating a doxycycline-inducible cell line. 786-
O cells were therefore transfected with a doxycycline regulatable
vector, and clonal lines were established (Fig. 7d). Of numerous
clones, the clone that exhibited the highest level of CPT1A
induction after 24 h of doxycycline administration was chosen
(clone #14). To verify that lipid accumulation was affected by
CPT1A expression in this subclone, cells were ﬁrst tested for
droplet formation in vitro in the presence of doxycycline or
vehicle (dimethylsulfoxide (DMSO)). As shown in Fig. 7e,
doxycycline was able to dramatically reduce lipid accumulation
in the cells, similar to the effects of adenoviral CPT1A expression
in the parental cells in Fig. 6c. Subsequently, clone #14 cells were
implanted subcutaneously in nude animals and tumor growth
was monitored. When average tumor volumes reached 100 mm3,
the animals were randomized and doxycycline was added to the
chow of one cohort of mice. Over the next 5 weeks, it became
evident that animals eating normal chow developed tumors at a
signiﬁcantly increased rate compared to the animals ingesting
doxycycline (p< 0.0001, two-way ANOVA) (Fig. 7f). Thus, we
conclude that CPT1A expression is incompatible with ccRCC
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tumor growth, and that HIF-mediated suppression of CPT1A is a
requisite step in ccRCC development in model systems.
CPT1A expression and activity are repressed in ccRCC samples.
To understand the clinical signiﬁcance of CPT1A suppression in
ccRCC, we queried cancer gene expression databases for CPT1A
levels in patient samples. We found statistically signiﬁcant reduc-
tions of CPT1A message in tumors compared to normal kidney
specimens in both the Beroukhim22 and Gumz23 studies (p<
0.0001 and p = 0.0003, respectively; Student’s t tests; Fig. 8a). We
next wished to determine if CPT1A expression associates with
patient outcome, and thus interrogated The Cancer Genome Atlas
(TCGA) database2. As shown in Fig. 8b, division of patients into
upper and low thirds by expression level resulted in a signiﬁcant
difference in the likelihood of survival in favor of those with higher
expression (p = 2.58 × 10−6, Log-rank test), implying the level of
suppression of CPT1A is related to the severity of disease. To
determine if differences in gene expression correlate with differ-
ences in enzymatic activity, we measured CPT1 activity in the
mitochondria of freshly isolated ccRCC tumors and compared to
activity in mitochondria from matched normal kidney specimens.
In seven samples, we found an average decrease in activity of 81%
in validated VHL mutant tumors compared to their normal tissues,
and found that CPT1A was repressed in all cases (Fig. 8c, d). We
also found robust lipid droplet formation in the tumors (Fig. 8e).
Together, the studies indicate that CPT1A repression is recapitu-
lated in human tumor samples, and that the level of repression may
have prognostic value.
Discussion
In the current work, we present data demonstrating that meta-
bolic adaptation in clear cell renal cell carcinoma resulting in
activation of lipid storage pathways is a necessary step in the
development of malignancy. We identify the rate-limiting enzyme
in fatty acid entry into the mitochondria (CPT1A) as a direct
target of transcriptional repression by the HIF1α and HIF2α
subunits through promoter silencing. Re-expression of VHL in
ccRCC cell lines results in degradation of HIF1α and HIF2α,
elevation of CPT1A message and protein, and inhibition of the
formation of lipid droplets. Accordingly, depletion of CPT1A in
VHL reconstituted cell lines restores the lipid deposition phe-
notype. The importance of CPT1A repression was determined in
re-expression studies, in which we observed an inhibition of lipid
deposition and a correlated inhibition of tumor growth. Finally,
we observed that in clinical samples, CPT1A expression is
reduced in tumors compared to normal kidneys, and signiﬁcantly
that CPT1A activity is reduced in mitochondria harvested from
tumor tissue compared to adjacent normal kidney tissue. Thus,
CPT1A expression is a critical target of the HIF pathway involved
in clear cell tumor etiology.
Altered metabolism is a well-recognized hallmark of cancer24,
and ccRCC offers perhaps one of the most visually convincing
examples. Metabolic changes in ccRCC include shifts to anaerobic
metabolism through the HIF-dependent activation of many genes
in the glycolytic pathway, reductive carboxylation of glutamine-
derived α-ketoglutarate as a carbon source in place of pyruvate in
the citric acid cycle, and increased utilization of the pentose
phosphate pathway11, 18, 25–27. The notable change histologically,
however, is the appearance of vast lipid and glycogen deposits
that ﬁll the cytoplasm of tumor cells28. It has been unclear until
recently whether lipid deposition in cancer cells promotes a
selective advantage to cancer cells, or whether lipid storage is a
passenger to altered energy metabolism. The Harris group,
however, demonstrated that hypoxia-induced-lipid storage in
breast and glioma cell lines is due to a HIF-dependent increase in
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fatty acid uptake via transcriptional regulation of fatty acid-
binding proteins FABP3 and FABP729. Importantly, interruption
of the pathway decreased lipid droplets and the tumorigenic
capacity of xenografts in mice while increasing cellular reactive
oxygen species (ROS), leading the authors to conclude that
hypoxia-driven lipid accumulation serves as a protective barrier
against oxidative stress-induced toxicity. Similarly, it was recently
published by the Simon group in clear cell renal tumors that lipid
deposits offer protection from hypoxia or pharmacologically
induced ER stress21. Both publications identify the lipid droplet
structural protein perilipin2 (known as PLIN2 or ADRP) as
hypoxia-regulated and critical for droplet formation.
Unlike other studies, however, the current work demonstrates a
key metabolic enzyme is essential for the lipid deposition phe-
notype. CPT1A, part of the CPT1 transport system, is the rate-
limiting component controlling the entry of fatty acids into the
mitochondria for beta oxidation. CPT1 catalyzes the transfer of
the acyl group from palmitoyl-Coenzyme A to carnitine to form
palmitoylcarnitine, which is subsequently transported across the
inner mitochondrial membrane in exchange for free carnitine by
carnitine-acylcarnitine translocase. Under hypoxic conditions,
decreasing the production of acetyl-CoA by beta oxidation in
addition to decreasing production of acetyl-CoA via decarbox-
ylation of pyruvate are logical adaptations to decreased oxygen
availability. HIF is responsible for inducing the expression of
PDK1 (pyruvate dehydrogenase kinase 1) that inhibits pyruvate
dehydrogensase25, and likewise we ﬁnd here that HIF also is
responsible for inhibiting the expression of CPT1A. Together,
HIF alters aerobic metabolism by diverting pyruvate to glycolysis,
and fatty acids to storage.
HIF functioning as a transcriptional repressor is unusual but not
undocumented17. The common way that hypoxia leads to
transcriptional repression is through the induction of transcrip-
tional repressors including DEC1, DEC2, ZEB1, ZEB2, Snail, and
REST. We tested two of the known repressors we thought might be
most relevant to metabolic changes (DEC1 and Snail) based on
prior publications suggesting DEC1 controls respiration18 and Snail
controls glucose metabolism19, but were unable to implicate them
in CPT1A regulation. Clearly further studies will be necessary to
determine how HIF functions differently on CPT1A than on acti-
vated targets, such as by identifying proteins that co-localize with
HIF on one promoter but not another. While our studies are by no
means exhaustive in this regard, the binding of HIF to a repressed
gene target that is negatively regulated strongly suggests the loca-
lization is mechanistically relevant. Notably, HIF activity in the case
of CPT1A suppression is sufﬁcient in the absence of other hypoxia-
regulated epigenetic regulators, such as the oxoglutarate-dependent
dioxygenases of the Jumonji family whose expression are not only
induced by hypoxia, but require low oxygen for activity. Reduction
of CPT1A message by HIF is seen in normoxia in VHL-deﬁcient
cells as well as in DMOG-treated cells in normoxia. A signiﬁcant
question that remains open is whether HIF localizes with a co-
repressor on CPT1A, and how the distinction is made between
activation or inhibition of a HIF transcriptional target.
Cancer cells frequently display alterations in lipid metabolism
as carbon demand for the formation of membranes and signaling
molecules is high in rapidly dividing tumor cells9. It has been
noted that while normal cells rely on fatty acid uptake as a major
source of fatty acids, tumor cells prefer to synthesize their fatty
acids30. We tested whether the elevated storage of fatty acids in
ccRCC tumor cells was due to increased uptake from extracellular
sources using a ﬂuorescently labeled cis-unsaturated fatty acid,
but found accordingly that uptake of the labeled fatty acid was
not altered. We also tested the role of the lipid transporter CD36,
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which is known to be hypoxia regulated14. Unlike the published
observations for hypoxic MCF7 and U87 cells29, therefore, the
renal lines we tested do not develop lipid droplets due to
increased lipid or fatty acid transport. We further found that
glucose but not glutamine was required for the formation of
droplets, which was surprising based on the recent ﬁndings
regarding the use of glutamine by renal cancer cells for the
production of citrate and subsequently lipogenesis11. We also
noted the reported sensitivity of VHL-deﬁcient renal cancer cells
to glutamine starvation, but remarkably the cells were still able to
store lipids in droplets. At present, it is unclear whether the
requirement for glucose is for the production of glycerol to make
triglycerides, or to make fatty acids via de novo synthesis. It is also
possible that the surviving tumor cells in glutamine-deprived
conditions acquire lipids from neighboring cells that have
undergone cell death31. What is clear, however, is that the fate of
fatty acids is drastically altered due to the repression of CPT1A
expression and activity.
A recent integrative analysis of metabolomics and metabolic
gene expression in ccRCC revealed a suppression of gluconeo-
genesis by uniform depletion of fructose-1,6-bisphosphatase-1
(FBP1) in a non-HIF-dependent manner26. By reducing FBP1,
ccRCC cells promote glycolysis and in theory leave glycerol for
use in lipid formation. Interestingly, a report describing a genetic
screen for shRNAs that could increase survival of renal proximal
epithelial cells (the proposed cell of origin for ccRCC) after
treatment with severe hypoxia (0.2% O2 for 48 h) identiﬁed both
FBP1 and CPT1A as candidate genes whose suppression led to
survival32. Thus, as both FBP1 and CPT1A are inhibitive of
tumor growth and cell survival under stress, both genes display
tumor suppressor phenotypes; though whether lipid deposition is
a common mechanism of the effect remains to be investigated.
Importantly, the discoveries surrounding the roles of these and
other genes in ccRCC suggest that pharmacologic approaches to
reverse the lipid deposition phenotype could have traction in
treating renal cancer. A similar argument has been made recently
in a mouse model of renal ﬁbrosis leading to kidney disease,
wherein it was observed that fatty acid oxidation is diminished
and lipid deposition is elevated33. Restoring fatty acid metabolism
with C75, a compound that induces CPT1 activity, led to
reduction or prevention of the ﬁbrotic phenotype. (Unfortu-
nately, however, C75 has also been argued to inhibit CPT1 in
other systems34.) Together, the observations make the case for
new therapeutics in renal cancer that target various aspects of the
characteristic changes in metabolism, including restoration of
function of FBP1 and CPT1A.
CPT1 may have a unique role in limiting tumor growth in
ccRCC. Studies have shown that expression of CPT1C, the brain
isoform of CPT1A, is elevated in lung cancer and promotes
tumor growth and resistance to metabolic stress35. In addition,
etomoxir, an irreversible CPT1 inhibitor increases reactive oxy-
gen species and cell death in glioblastoma cells. Finally, leukemia
cells are also sensitive to inhibition of fatty acid oxidation. In non-
tumor cells, CPT1 has an important role in angiogenesis because
fatty acid oxidation has been shown to be required for nucleotide
synthesis for DNA replication36. Thus, our observation that
CPT1A repression is critical for ccRCC growth identiﬁes a tumor-
speciﬁc metabolic adaptation of renal cancer and supports the
concept that limiting FA availability by increasing oxidation
could have clinical potential9. Efforts to develop speciﬁc inducers
of CPT1A expression or activity may therefore be warranted as a
novel therapeutic approach.
Methods
Cell culture and reagents. All cell lines were STR (short tandem repeat) veriﬁed
and mycoplasma tested. RCC4, RCC4 VHL (Sigma); RCC10, RCC10 VHL (gift of
Dr Amato Giaccia); and 786-O, 786-O VHL (gift of Dr Sandra Turcotte) cells were
maintained in high-glucose DMEM medium supplemented with 10% bovine calf
serum at 37 °C and 5% CO2. For hypoxia incubation, a 1% O2 environment was
generated in a Ruskinn InVivo2 Hypoxia chamber. Lipofectamine 2000 (Life
Technologies) was used for transfections. Crystal violet staining was performed
with 0.05% crystal violet in 1% formaldehyde and 1% methanol. BrdU labeling was
performed by supplementing cells with 0.03 mg/ml for 24 h, and staining with anti-
BrdU (Cell Signaling) followed by Texas red-conjugated goat anti-mouse IgG.
Non-speciﬁc FITC ﬂuorescence was used as a background cell stain.
Oil Red O staining. Cells plated in 12-well plates at triplicate were rinsed with PBS
twice, and ﬁxed with 10% formaldehyde for 1 h. They were then rinsed with 60%
isopropanol for 5 min, stained with 3 mg/ml Oil Red O for 4 min, and washed with
water three times. For Oil Red O quantiﬁcation, the cells were dried, and 250 μl of
isopropanol was added and incubated for 3 min; the eluted solution was read at
510 nm. To normalize for cell mass, the cells were subsequently stained with sul-
forhodamine B following a published protocol37, and read at 564 nm wavelength.
Fresh frozen, OCT-embedded tumor sections were stained with a similar protocol
after sectioning 8 μm slices on a cryostat.
Real-time PCR. TRIzol reagent was used for RNA isolation. RT-PCR was per-
formed using standard procedures and normalized to β-actin. Brieﬂy, RNA samples
were reverse transcribed into cDNA using MMLV-RT, and quantitative PCR was
performed with SYBR green master mix or TaqMan Fast Advanced Master Mix
(Life Technologies) on the StepOne plus PCR system (Applied Biosystems). Primer
sequences were β-actin F: 5′-CATGTACGTTGCTATCCAGGC-3′ R: 5′-CTCCTT
AATGTCACGCACGAT-3′; CD36 TaqMan Hs01567187; CPT1A F: 5′-GAAGAT
GGCAGAAGCTCACC-3′ R: 5′-TGGCGTACATCGTTGTCAT-3′; GLUT1 F: 5′-
GGCCAAGAGTGTGCTAAAGAA-3′ R: 5′-ACAGCGTTGATGCCAGACAG-3′;
Snail TaqMan Hs00195591; CDH1 TaqMan Hs1023895; DEC1 F: 5′-CCTTGA
AGCATGTGAAAGCA-3′ R: 5′-GCTTGGCCAGATACTGAAGC-3′; PGC1α F: 5′-
GTCAACAGCAAAAGCCACAA-3′ R: 5′-TCTGGGGTCAGAGGAAGAGA-3′;
PLIN2 F: 5′-CCTGCTCTTCGCCTTTCG-3′ R: 5′-TGCAACGGATGCCATTT
TT-3′.
Western blots. Western blots were performed using standard procedures. Brieﬂy,
protein lysates were created with a 9M urea lysis buffer (7.5 mM Tris/HCl, pH 8.0),
followed by sonication using a Sonic dismembrator and centrifugation at 10,000
rpm for 20 min. Protein concentrations were determined by the BCA (Bicincho-
ninic acid) method on a NanoDrop 1000. Between 50 and 100 μg of protein was
electrophoresed on polyacrylamide gels, and transferred to methylcellulose mem-
branes. Antibodies against β-actin (1:10,000; Sigma, Cat# A1978), VHL (1:1000;
Cell Signaling, Danvers, MA, Cat# 2738), HIF1α (1:200; Santa Cruz, Cat# sc-
53546), HIF2α (1:500; Novus, Cat# NB100-122), or CPT1A (1:200; described38
were used to decorate the membranes, and developed by enhanced chemilumi-
nescence. Uncropped images are provided as supplementary data (Supplementary
Fig. 1).
Chromatin immunoprecipitation (ChIP). ChIP was performed as previously
described39. Brieﬂy, semiconﬂuent 15 cm plates were ﬁxed with 1% formaldehyde
for 10 min and quenched with glycine. Samples were then scraped and pelleted,
and nuclei were prepared with SDS lysis under hypotonic conditions. Sonication
was used to reduce genomic DNA size to the range of 500–1000 base pairs. The
samples were quantiﬁed, and 1 mg of chromatin was used to immunoprecipitate
with 5–10 μg of indicated antibodies. Primer sequences were neg: 5′-CCCAT-
GAAGAAGCTCAGGTC-3′, 5′-AGGCCATTTGAAGTGGTCAG-3′; 1: 5′-ATTA-
TAGGCACCTGCCACCA-3′, 5′-CTAGCACTTCGGGGCTGAG-3′; 2: 5′-
ACCCAGCTGGTCCTCTTTTA-3′, 5′-ACAAACATGAGCCACTGCAC-3′; 3: 5′-
CAAAAATCAGCCGTGGTG-3′, 5′-TCTCTCTTCGTCACCCAGTC-3′; 4: 5′-
ATCCCGTGTTCAGAGCAGAC-3′, 5′-AGGACAGAACAGGGTGATG-3′; 5: 5′-
CATGGTGATGCACGTCTGTA-3′, 5′-CCGTTATGTCCACAAATTCCTT-3′; 6:
5′-CGGTGAGAATGACAGTCCAG-3′, 5′-TTGTCTGGACCACCAGTGAG-3′; 7:
5′-CCTGTGTCACCAAAATGTCG-3′, 5′-CCCCACCATTGCAGGTATAA-3′; 8:
5′-GCTTCTTTCGGTTTGTCAGG-3′, 5′-ATCGGCCCTCATCTTTGAGT-3′;
CPT1A proximal to start site: 5′-CTCAGCCAATCCGCTGCT-3′, 5′-CCTCACC-
GAGTCAGCTACG-3′; GLUT1: 5′-CTAGGGGAGCAGACGGAGAG-3′, 5′-
GAGCACATGGCCTCCTTCC-3′.
Fatty acid uptake assay. The QBTTM fatty acid uptake assay kit was used
(Molecular Devices). Brieﬂy, BODIPY-dodecanoic acid ﬂuorescent fatty acid
analog (BODIPY 500/512, C1, C12) was added to the medium of 80,000 cells
seeded in triplicate in 24-well plates, and the cells were observed over a 2-day
period. Fluorescence was measured at indicated time intervals on a Tecan GENios
ﬂuorescent plate reader.
DNA constructs. Lentiviral transduction of shRNA was performed with pLKO.1
plasmids from Sigma: HIF1α (TRCN0000003809), HIF2α (TRCN0000003803),
CPT1A (TRCN000036279, TRCN000036282, TRCN000036283), Snail
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(TRCN000063819), and DEC1 (TRCN0000013249 and TRCN0000013251). shGFP
was used as a control. CPT1AM overexpression was accomplished by adenoviral
transfection as described40. Cells were infected at a multiplicity of infection of 20.
Doxycycline-inducible CPT1AM expression was performed by cloning CPT1AM
into pTRE2 and cotransfecting with pMA2640 into 786-O cells. Clonal lines were
created.
Mouse tumor assays. Tumor assays were performed in 8-week-old athymic
female BALB/c nude mice obtained from an in-house colony. Subcutaneous
injections were performed with 2 × 106 786-O cells in 100 μl of saline. Tumor
growth was monitored and measured twice weekly with calipers; tumor volumes
were calculated by the formula V = 1/2 L ×W2. Tumors were removed and portions
were prepared for immunoblot analysis, and portions were rapidly frozen in OCT
on dry ice. Eight micron sections were cut and ﬁxed in 3.7% paraformaldehyde for
30 min, and followed by blocking (1% BSA in PBS) for 30 min, 1:5000 anti-CPT1A
primary Ab, and 1:5000 secondary Ab (anti-rabbit-conjugated Alexa Fluor- 488
nm, Invitrogen). Serial sections were stained with Oil Red O as described above.
For doxycycline induction experiments, animals were fed Dox Diet (S3888) or
control diet (S4207) from Bioserv.
CPT1A activity measurements. Mitochondria from normal and tumor tissue
were isolated after tissue homogenization in an isotonic cold sucrose solution (30%
sucrose, 1x PBS) and separated by centrifugation for 15 min at 600xg, and the
supernatant was centrifuged again for 20 min at 12,000xg. The pellet was re-
suspended in 2 ml of homogenization buffer (70 mM sucrose, 220 mM manitol,
5mM HEPES, 2 mM EDTA pH 7.4), centrifuged for 10 min at 7000xg, washed and
ﬁnally re-suspended in 0.5 ml of homogenization buffer. The concentration of the
mitochondria was quantiﬁed by BCA assay; 10 μg was used for the CPT1 activity
assay. The malonyl-CoA-sensitive carnitine palmitoyltransferase activitiy was
measured as described41 except that the production of palmitoylcarnitine was
measured using HPLC-MS/MS42.
Metabolic readouts. Oxygen consumption was measured on a Seahorse XFp
Analyzer according to the manufacture’s recommendations. Citrate and acetyl-
CoA were measured using gas chromatography mass spectrometry as described43–
45. Acetyl-CoA was assayed at the University of Pennsylvania Quantitative Pro-
teomics Core.
VHL sequencing. To determine VHL status on patient samples, genomic DNA
was prepared and exons 1, 2, and 3 were PCR ampliﬁed and sequenced. Mutations
and deletions were revealed by comparison to NCBI sequences.
Statistics. All assays were performed at least three times, and results are expressed
as means± standard deviations. Analyses were performed with GraphPad Prism
6.01. Unpaired two-tailed Student’s t tests or two-way ANOVA were performed to
determine signiﬁcance. p values ≤0.05 were considered signiﬁcant.
Study approval. Human tissue samples were collected under IRB approval (Cle-
veland Clinic Foundation, IRB 4630) with written informed consent of all patients.
IACUC approval was obtained for all animal experiments (Case Western Reserve
University IACUC 0155).
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article or from the corresponding author on rea-
sonable request.
Received: 12 October 2016 Accepted: 30 October 2017
References
1. Ericsson, J. L., Seljelid, R. & Orrenius, S. Comparative light and electron
microscopic observations of the cytoplasmic matrix in renal carcinomas.
Virchows. Arch. Pathol. Anat. Physiol. Klin. Med. 341, 204–223 (1966).
2. Cancer Genome Atlas Research Network. T. Comprehensive molecular
characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
3. Young, A. C. et al. Analysis of VHL gene alterations and their relationship to
clinical parameters in sporadic conventional renal cell carcinoma. Clin. Cancer
Res. 15, 7582–7592 (2009).
4. Nickerson, M. L. et al. Improved identiﬁcation of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726–4734 (2008).
5. Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein:
O2 sensing and cancer. Nat. Rev. Cancer 8, 865–873 (2008).
6. Najjar, Y. G. & Rini, B. I. Novel agents in renal carcinoma: a reality check. Ther.
Adv. Med. Oncol. 4, 183–194 (2012).
7. Lendahl, U., Lee, K. L., Yang, H. & Poellinger, L. Generating speciﬁcity and
diversity in the transcriptional response to hypoxia. Nat. Rev. Genet. 10,
821–832 (2009).
8. Tun, H. W. et al. Pathway signature and cellular differentiation in clear cell
renal cell carcinoma. PLoS ONE 5, e10696 (2010).
9. Currie, E. et al. Cellular fatty acid metabolism and cancer. Cell Metab. 18,
153–161 (2013).
10. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates
lipogenesis under hypoxia. Nature 481, 380–384 (2012).
11. Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated
by citrate levels and sensitizes VHL-deﬁcient cells to glutamine deprivation. Cell
Metab. 17, 372–385 (2013).
12. Shechter, Y. & Henis, Y. I. Cis-unsaturated fatty acids induce both lipogenesis
and calcium binding in adipocytes. Biochim. Biophys. Acta 805, 89–96 (1984).
13. Last, A. R. & Wilson, S. A. Low-carbohydrate diets. Am. Fam. Physician 73,
1942–1948 (2006).
14. Mwaikambo, B. R., Yang, C., Chemtob, S. & Hardy, P. Hypoxia up-regulates
CD36 expression and function via hypoxia-inducible factor-1- and
phosphatidylinositol 3-kinase-dependent mechanisms. J. Biol. Chem. 284,
26695–26707 (2009).
15. Chabowski, A., Gorski, J., Calles-Escandon, J., Tandon, N. N. & Bonen, A.
Hypoxia-induced fatty acid transporter translocation increases fatty acid
transport and contributes to lipid accumulation in the heart. FEBS Lett. 580,
3617–3623 (2006).
16. Cal, R. et al. Low-density lipoprotein receptor-related protein 1 mediates
hypoxia-induced very low density lipoprotein-cholesteryl ester uptake and
accumulation in cardiomyocytes. Cardiovasc. Res. 94, 469–479 (2012).
17. Cavadas, M. A., Cheong, A. & Taylor, C. T. The regulation of transcriptional
repression in hypoxia. Experimental Cell Res. https://doi.org/10.1016/j.
yexcr.2017.02.024 (2017).
18. LaGory, E. L. et al. Suppression of PGC-1alpha is critical for reprogramming
oxidative metabolism in renal cell carcinoma. Cell Rep. 12, 116–127 (2015).
19. Bian, X. L. et al. Nur77 suppresses hepatocellular carcinoma via switching
glucose metabolism toward gluconeogenesis through attenuating
phosphoenolpyruvate carboxykinase sumoylation. Nat. Commun. 8, 14420
(2017).
20. Evans, A. J. et al. VHL promotes E2 box-dependent E-cadherin transcription by
HIF-mediated regulation of SIP1 and snail. Mol. Cell Biol. 27, 157–169 (2007).
21. Qiu, B. et al. HIF2alpha-dependent lipid storage promotes endoplasmic
reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 5,
652–667 (2015).
22. Beroukhim, R. et al. Patterns of gene expression and copy-number alterations
in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of
the kidney. Cancer Res. 69, 4674–4681 (2009).
23. Gumz, M. L. et al. Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin. Cancer Res. 13, 4740–4749
(2007).
24. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
25. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1
mediates adaptation to hypoxia by actively downregulating mitochondrial
oxygen consumption. Cell Metab. 3, 187–197 (2006).
26. Li, B. et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature 513, 251–255 (2014).
27. Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell
carcinoma. Cancer Cell 29, 104–116 (2016).
28. Kwon, T. J., Ro, J. Y. & Mackay, B. Clear-cell carcinoma: an ultrastructural
study of 57 tumors from various sites. Ultrastruct. Pathol. 20, 519–527 (1996).
29. Bensaad, K. et al. Fatty acid uptake and lipid storage induced by HIF-1alpha
contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9,
349–365 (2014).
30. Medes, G., Thomas, A. & Weinhouse, S. Metabolism of neoplastic tissue. IV A
study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13, 27–29
(1953).
31. Alves, B. et al. Hydrolysis of tumor cell lipids after CTL-mediated death. Int.
Immunol. 21, 543–553 (2009).
32. Zynda, E. R. et al. An RNA interference screen identiﬁes new avenues for
nephroprotection. Cell Death Differ. https://doi.org/10.1038/cdd.2015.128
(2015).
33. Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells
has a key role in kidney ﬁbrosis development. Nat. Med. 21, 37–46 (2015).
34. Bentebibel, A. et al. Novel effect of C75 on carnitine palmitoyltransferase I
activity and palmitate oxidation. Biochemistry 45, 4339–4350 (2006).
35. Zaugg, K. et al. Carnitine palmitoyltransferase 1C promotes cell survival and
tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041–1051
(2011).
36. Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial
cells. Nature 520, 192–197 (2015).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01965-8 ARTICLE
NATURE COMMUNICATIONS |8:  1769 |DOI: 10.1038/s41467-017-01965-8 |www.nature.com/naturecommunications 11
37. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity
screening. Nat. Protoc. 1, 1112–1116 (2006).
38. Lee, K., Kerner, J. & Hoppel, C. L. Mitochondrial carnitine palmitoyltransferase
1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J. Biol.
Chem. 286, 25655–25662 (2011).
39. Pasupuleti, V. et al. Dysregulated D-dopachrome tautomerase, a hypoxia-
inducible factor-dependent gene, cooperates with macrophage migration
inhibitory factor in renal tumorigenesis. J. Biol. Chem. 289, 3713–3723 (2014).
40. Malandrino, M. I. et al. Enhanced fatty acid oxidation in adipocytes and
macrophages reduces lipid-induced triglyceride accumulation and
inﬂammation. Am. J. Physiol. Endocrinol. Metab. 308, E756–E769 (2015).
41. Hoppel, C. L., Kerner, J., Turkaly, P., Turkaly, J. & Tandler, B. The malonyl-
CoA-sensitive form of carnitine palmitoyltransferase is not localized exclusively
in the outer membrane of rat liver mitochondria. J. Biol. Chem. 273,
23495–23503 (1998).
42. Minkler, P. E., Stoll, M. S., Ingalls, S. T., Kerner, J. & Hoppel, C. L. Quantitative
acylcarnitine determination by UHPLC-MS/MS--Going beyond tandem MS
acylcarnitine “proﬁles”. Mol. Genet. Metab. 116, 231–241 (2015).
43. Yang, L. et al. Metabolomic and mass isotopomer analysis of liver
gluconeogenesis and citric acid cycle: II. Heterogeneity of metabolite labeling
pattern. J. Biol. Chem. 283, 21988–21996 (2008).
44. Kombu, R. S., Brunengraber, H. & Puchowicz, M. A. Analysis of the citric acid
cycle intermediates using gas chromatography-mass spectrometry. Methods
Mol. Biol. 708, 147–157 (2011).
45. Zhang, Y., Zhang, S., Marin-Valencia, I. & Puchowicz, M. A. Decreased carbon
shunting from glucose toward oxidative metabolism in diet-induced ketotic rat
brain. J. Neurochem. 132, 301–312 (2015).
Acknowledgements
This work was supported by the following grants: American Cancer Society 121762-RSG-
12-097-01-CCG, NIH R21 CA178157-01A1, AACR 14-60-36-WELF, and CTSC
4UL1TR000439. The Cytometry and Microscopy Core Facility of the Case Compre-
hensive Cancer Center, which is supported by P30CA43703, was used in this study. We
also thank Thomas F. Peterson, Jr, for his generosity.
Author contributions
W.D. designed and performed the experiments and wrote the paper; L.Z., A.B.-M., and
B.A. performed the experiments; J.K. designed the experiments; C.L.H. designed and
performed the experiments; M.P. designed the experiments; D.S., L.H., B.I.R., and S.C.
contributed reagents; S.M.W. designed the experiments and wrote the paper.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-01965-8.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01965-8
12 NATURE COMMUNICATIONS | 8:  1769 |DOI: 10.1038/s41467-017-01965-8 |www.nature.com/naturecommunications
